Shaker Investments LLC OH Has $430,000 Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Shaker Investments LLC OH trimmed its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 42.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,085 shares of the biotechnology company’s stock after selling 42,627 shares during the period. Shaker Investments LLC OH’s holdings in Iovance Biotherapeutics were worth $430,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of IOVA. Assenagon Asset Management S.A. acquired a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at about $12,927,000. Principal Financial Group Inc. grew its position in Iovance Biotherapeutics by 59.0% in the third quarter. Principal Financial Group Inc. now owns 4,033,184 shares of the biotechnology company’s stock worth $37,872,000 after acquiring an additional 1,496,941 shares in the last quarter. State Street Corp increased its stake in shares of Iovance Biotherapeutics by 4.6% during the 3rd quarter. State Street Corp now owns 13,201,978 shares of the biotechnology company’s stock worth $123,967,000 after purchasing an additional 576,801 shares during the last quarter. Barclays PLC raised its holdings in shares of Iovance Biotherapeutics by 118.8% during the 3rd quarter. Barclays PLC now owns 604,584 shares of the biotechnology company’s stock valued at $5,677,000 after purchasing an additional 328,284 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of Iovance Biotherapeutics by 399.4% during the 3rd quarter. Victory Capital Management Inc. now owns 144,280 shares of the biotechnology company’s stock valued at $1,355,000 after purchasing an additional 115,387 shares in the last quarter. Institutional investors and hedge funds own 77.03% of the company’s stock.

Analyst Upgrades and Downgrades

IOVA has been the topic of several recent research reports. UBS Group assumed coverage on Iovance Biotherapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $17.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a research report on Wednesday, November 6th. Finally, Piper Sandler cut their target price on shares of Iovance Biotherapeutics from $10.00 to $7.50 and set a “neutral” rating for the company in a research report on Friday, January 31st. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $22.69.

Iovance Biotherapeutics Stock Performance

IOVA opened at $5.32 on Tuesday. The stock’s 50 day simple moving average is $6.99 and its 200-day simple moving average is $8.89. Iovance Biotherapeutics, Inc. has a 1 year low of $5.30 and a 1 year high of $18.33.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.